Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
PLoS One
    January 2025
  1. KITAW TA, Haile RN
    Virological outcomes of antiretroviral therapy and its determinants among HIV patients in Ethiopia: Implications for achieving the 95-95-95 target.
    PLoS One. 2025;20:e0313481.
    >> Share

  2. YOKOMAKU Y, Teruya K, Watanabe D, Endo T, et al
    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort.
    PLoS One. 2025;20:e0313338.
    >> Share

  3. MONTANO MA, Sindelo S, Fata A, Rousseau E, et al
    Urine tenofovir adherence testing: Perspectives of recently diagnosed South African adolescents and young adults with HIV accessing care via mobile HIV clinics.
    PLoS One. 2025;20:e0318308.
    >> Share

  4. YOKOMAKU Y, Noda T, Imahashi M, Nishioka Y, et al
    Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database.
    PLoS One. 2025;20:e0317655.
    >> Share

  5. YAZIE TS, Shiferaw WS, Gebeyehu AA, Teshome AA, et al
    Chronic kidney disease among people living with HIV on TDF based regimen: A systematic review and meta-analysis.
    PLoS One. 2025;20:e0318068.
    >> Share

  6. GWASUPIKA J, Hamer DH, Daka V, Chikwanda E, et al
    Antibiotic prescription patterns and associated symptoms in children living with HIV at Arthur Davison Children's Hospital in Ndola, Zambia.
    PLoS One. 2025;20:e0316735.
    >> Share

  7. MUHINDO R, King R, Irie W, Mujugira A, et al
    Associations with HIV preexposure prophylaxis use by cisgender female sex workers in two Ugandan cities.
    PLoS One. 2025;20:e0320065.
    >> Share

  8. MUTUKWA M, Kaonga P, Mfula C, Mwansa MM, et al
    Prevalence of detectable viral load and its associated factors among adult patients receiving ART in Choma District, Zambia.
    PLoS One. 2025;20:e0320571.
    >> Share

  9. KOFFI JJ, Boni SP, Mba L, Bitty-Anderson A, et al
    Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients.
    PLoS One. 2025;20:e0317223.
    >> Share

  10. MOSES N, Bukke SPN, Goruntla N, Mwandah DC, et al
    Prevalence and factors associated with adverse drug reactions among patients on highly active antiretroviral therapy at a tertiary hospital in south western Uganda: A cross-sectional study.
    PLoS One. 2025;20:e0321015.
    >> Share

  11. SIAME L, Mutalange M, Chanda C, Sakala M, et al
    The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multicenter cohort study.
    PLoS One. 2025;20:e0323618.
    >> Share

  12. KARA Y, Ozkan YS, Ullah A, Hamed YS, et al
    QSPR modeling of some COVID-19 drugs using neighborhood eccentricity-based topological indices: A comparative analysis.
    PLoS One. 2025;20:e0321359.
    >> Share

  13. ELGAMMAL Y, Salama EA, Seleem MN
    HIV protease inhibitors restore amphotericin B activity against Candida.
    PLoS One. 2025;20:e0324080.
    >> Share

  14. PRAGUYLERTLUCK W, Kaewdech A, Chamroonkul N, Piratvisuth T, et al
    Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B.
    PLoS One. 2025;20:e0324897.
    >> Share

  15. ZHANG C, Wen J, Li Y
    A real-world disproportionality analysis of Tenofovir Alafenamide (TAF): Data mining of the FDA adverse event reporting system (FAERS).
    PLoS One. 2025;20:e0324675.
    >> Share

  16. YAN H, Hu S, Zhang H, Zhou Y, et al
    Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19.
    PLoS One. 2025;20:e0309875.
    >> Share

  17. AMUTUHAIRE W, Castelnuovo B, Brusselaers N, Nabwana M, et al
    Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.
    PLoS One. 2025;20:e0325020.
    >> Share

  18. LIN Y, Lin X, Xia R, Chen J, et al
    Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.
    PLoS One. 2025;20:e0327298.
    >> Share

  19. KAYINDA F, Awor P, Mahaba T, Muganzi AM, et al
    Prevalence of HIV drug resistance, its correlates and common mutations among people living with HIV failing on ART in northern Uganda: A cross-sectional study.
    PLoS One. 2025;20:e0320623.
    >> Share

  20. MUCHINTA E, Chabala FW
    Chronic kidney disease among HIV-positive Zambian adults with tenofovir-associated nephrotoxicity at University Teaching Hospital (UTH) in Lusaka.
    PLoS One. 2025;20:e0330356.
    >> Share

  21. SEQUERA-ARQUELLADAS S, Vivancos MJ, Vinuesa D, Collado A, et al
    Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.
    PLoS One. 2025;20:e0323167.
    >> Share

  22. DEMISSIE AA, Rensburg EJV
    Healthcare providers' perspectives of barriers and facilitators to highly active antiretroviral therapy adherence among HIV-positive women in Southern Ethiopia: A qualitative study.
    PLoS One. 2025;20:e0312980.
    >> Share

  23. WEN J, Ma X, Zhou X, Kissell RC, et al
    Molecular basis for the activation of the bitter taste receptor TAS2R14 by Ritonavir.
    PLoS One. 2025;20:e0332704.
    >> Share

    January 2024
  24. JIWA NA, Ketang'enyi E, Nganyanyuka K, Mbwanji R, et al
    Factors associated with the acceptability of Lopinavir/Ritonavir formulations among children living with HIV/AIDS attending care and treatment clinics in Mbeya and Mwanza, Tanzania.
    PLoS One. 2024;19:e0292424.
    >> Share

  25. PEREZ-MARTINEZ L, Romero L, Verdugo-Sivianes EM, Munoz-Galvan S, et al
    Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.
    PLoS One. 2024;19:e0286201.
    >> Share

  26. SHIDA H, Komamine M, Kajiyama K, Waki T, et al
    Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan.
    PLoS One. 2024;19:e0297679.
    >> Share

  27. FAYA CASTILLO JE, Zapata Dongo RJ, Wong Chero PA, Infante Varillas SF, et al
    Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
    PLoS One. 2024;19:e0295966.
    >> Share

  28. WU L, Wang Q, Gao QC, Shi GX, et al
    Potential mechanisms and drug prediction of Rheumatoid Arthritis and primary Sjogren's Syndrome: A public databases-based study.
    PLoS One. 2024;19:e0298447.
    >> Share

  29. RUNGMAITREE S, Werarak P, Pumpradit W, Phongsamart W, et al
    A pilot program of HIV pre-exposure prophylaxis in Thai youth.
    PLoS One. 2024;19:e0298914.
    >> Share

  30. KAMAU SG, Akatusasira R, Namatovu A, Kibet E, et al
    The level of antiretroviral therapy (ART) adherence among orphan children and adolescents living with HIV/AIDS: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0295227.
    >> Share

  31. MINJA M, Mbilinyi T, Mkinga B, Philipo EG, et al
    Prevalence, treatment, and factors associated with cryptococcal meningitis post introduction of integrase inhibitors antiretroviral based regimens among People Living with HIV in Tanzania.
    PLoS One. 2024;19:e0294940.
    >> Share

  32. SHAMU T, Egger M, Mudzviti T, Chimbetete C, et al
    Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    PLoS One. 2024;19:e0293162.
    >> Share

  33. SACKEYA E, Beru MM, Angmortey RN, Opoku DA, et al
    Survival trends among people living with human immunodeficiency virus on antiretroviral treatment in two rural districts in Ghana.
    PLoS One. 2024;19:e0290810.
    >> Share

  34. CACERES-PEREZ AR, Suarez-Gonzalez J, Santovena-Estevez A, Farina JB, et al
    Quality assessment of oral antimalarial and antiretroviral medicines used by public health systems in Sahel countries.
    PLoS One. 2024;19:e0303289.
    >> Share

  35. MIURA M, Nishino M, Kawaguchi K, Li S, et al
    Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy.
    PLoS One. 2024;19:e0299424.
    >> Share

  36. AGYARE GYANE F, Modey E, Maya E, Bonney EY, et al
    Prevalence and risk factors associated with high-risk human papillomavirus infection among women living with HIV (WLWH) at a tertiary health facility in Accra, Ghana.
    PLoS One. 2024;19:e0303535.
    >> Share

  37. BUTT AA, Yan P, Shaikh OS
    Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    PLoS One. 2024;19:e0298254.
    >> Share

  38. AMANI B, Amani B
    Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0298772.
    >> Share

  39. FACHA W, Tadesse T, Wolka E, Astatkie A, et al
    Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    PLoS One. 2024;19:e0305331.
    >> Share

  40. YU XL, Sun W, Liu L, Hong K, et al
    Urinary alpha 1-microglobulin and beta 2-microglobulin as markers of early kidney injury in HIV-positive male patients on tenofovir-based antiretroviral therapy.
    PLoS One. 2024;19:e0303442.
    >> Share

  41. CHEBET JJ, Akyoo WO, Goymann H, Harling G, et al
    Demonstrating service delivery models for effective initiation and retention on pre-exposure prophylaxis (PrEP) among female bar workers in Dar es Salaam, Tanzania: A double randomized intervention study protocol.
    PLoS One. 2024;19:e0304077.
    >> Share

  42. BRKIC-JOVANOVIC N, Karaman M, Andric V, Maric D, et al
    Neurocognitive profile in HIV subjects on INSTI-regimen- one year follow up: Is there room for optimism?
    PLoS One. 2024;19:e0306278.
    >> Share

  43. SABATEEN A, Sadaqa D, Nino T, Zaghal G, et al
    Evaluation of COVID-19 rapid antigen test against polymerase chain reaction test in immunocompromised patients.
    PLoS One. 2024;19:e0306396.
    >> Share

  44. ALKASHEF NM, Seleem MN
    Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.
    PLoS One. 2024;19:e0308216.
    >> Share

  45. DOS MUCHANGOS V, Chambal L, Nilsson C, Sevene E, et al
    HIV and hepatitis B virus co-infection in Mozambique: Policy review and health professionals' knowledge and practices.
    PLoS One. 2024;19:e0301305.
    >> Share

  46. LUWAYA EL, Mwape L, Bwalya K, Siakabanze C, et al
    Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
    PLoS One. 2024;19:e0308869.
    >> Share

  47. LI J, Shen C, Liu ZW, Pu FL, et al
    Chinese herbal medicine for patients living with HIV in Guangxi province, China: A propensity score matching analysis of real-world data.
    PLoS One. 2024;19:e0304332.
    >> Share

  48. WANG Y, Yang Z, Li J, Wu Z, et al
    The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou.
    PLoS One. 2024;19:e0305461.
    >> Share

  49. KURETU A, Mothibe M, Ngubane P, Sibiya N, et al
    Elucidating the effect of drug-induced mitochondrial dysfunction on insulin signaling and glucose handling in skeletal muscle cell line (C2C12) in vitro.
    PLoS One. 2024;19:e0310406.
    >> Share

  50. BENNETT CL, Magagnoli J, Gundabolu K, Georgantopoulos P, et al
    A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases.
    PLoS One. 2024;19:e0308205.
    >> Share

  51. GUDINA A, Wordofa M, Urgessa F
    Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia.
    PLoS One. 2024;19:e0310239.
    >> Share

  52. LEE SY, Lin YC, Chen CP, Cheng SH, et al
    Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.
    PLoS One. 2024;19:e0314003.
    >> Share

  53. MOKOENA H, Mabhida SE, Choshi J, Sekgala MD, et al
    Soluble P-selectin as an inflammatory mediator potentially influencing endothelial activation in people living with HIV in sub-rural areas of Limpopo, South Africa.
    PLoS One. 2024;19:e0310056.
    >> Share

  54. MERCHANT E, Solleveld P, Gibas K, Krakower D, et al
    Health care providers' decision-making and early adoption of tenofovir alafenamide for HIV preexposure prophylaxis: An inductive qualitative study.
    PLoS One. 2024;19:e0311591.
    >> Share

  55. BURNS N, Salama EA, Seleem MN
    Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species.
    PLoS One. 2024;19:e0314474.
    >> Share

  56. SUN J, Deng X, Huang J, He G, et al
    Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
    PLoS One. 2024;19:e0316573.
    >> Share

  57. ZEBALLOS D, Magno L, Soares F, Pinto Junior JA, et al
    Performance of indirect adherence measures for daily oral pre-exposure prophylaxis for HIV among adolescent men who have sex with men and transgender women in Brazil.
    PLoS One. 2024;19:e0310861.
    >> Share

    January 2023
  58. FROLA CE, Aristegui I, Figueroa MI, Radusky PD, et al
    Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
    PLoS One. 2023;18:e0279996.
    >> Share


  59. Correction: Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
    PLoS One. 2023;18:e0281190.
    >> Share

  60. CHI BH, Sebikari D, Brummel SS, DeMarrais P, et al
    Progesterone and prolactin levels in pregnant women living with HIV who delivered preterm and low birthweight infants: A nested case-control study.
    PLoS One. 2023;18:e0280730.
    >> Share

  61. BYONANEBYE DM, Polizzotto MN, Parkes-Ratanshi R, Musaazi J, et al
    Prevalence and incidence of hypertension in a heavily treatment-experienced cohort of people living with HIV in Uganda.
    PLoS One. 2023;18:e0282001.
    >> Share

  62. BEAUCHAMP G, Hosek S, Donnell DJ, Chan KCG, et al
    Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
    PLoS One. 2023;18:e0281728.
    >> Share

  63. HERON JE, McManus H, Vickers T, Ryan K, et al
    Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study.
    PLoS One. 2023;18:e0280339.
    >> Share

  64. MENGISTU ST, Ghebremeskel GG, Achila OO, Abrehe MB, et al
    Prevalence and factors associated with pediatric HIV therapy failure in a tertiary hospital in Asmara, Eritrea: A 15-year retrospective cohort study.
    PLoS One. 2023;18:e0282642.
    >> Share

  65. PERETTI M, Rebaudet S, Chiche L, Pegliasco H, et al
    Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study.
    PLoS One. 2023;18:e0283165.
    >> Share

  66. ADEYEMI OA, Nowak RG, Marzinke M, Morgan D, et al
    Correlates of self-reported and biomarker based adherence to daily oral HIV pre-exposure prophylaxis among a cohort of predominantly men who have sex with men in Nigeria.
    PLoS One. 2023;18:e0282999.
    >> Share

  67. BAASSI M, Moussaoui M, Soufi H, Rajkhowa S, et al
    Towards designing of a potential new HIV-1 protease inhibitor using QSAR study in combination with Molecular docking and Molecular dynamics simulations.
    PLoS One. 2023;18:e0284539.
    >> Share

  68. WECHE M, DeSantis AJ, McGee MY, Enten GA, et al
    Effects of chemokine (C-C motif) receptor 2 and 3 antagonists in rat models of hemorrhagic shock.
    PLoS One. 2023;18:e0284472.
    >> Share

  69. NIU D, Tang H, Chen F, Zhao D, et al
    Treatment failure and associated factors among people living with HIV on highly active antiretroviral therapy in mainland China: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0284405.
    >> Share

  70. VAN DEN HOF M, Smit C, Rossum AMCV, Fraaij PLA, et al
    Adoption is not associated with immunological and virological outcomes in children with perinatally acquired HIV infection in the Netherlands.
    PLoS One. 2023;18:e0284395.
    >> Share

  71. VOLKOW P, Chavez Galan L, Ramon-Luing L, Cruz-Velazquez J, et al
    Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial.
    PLoS One. 2023;18:e0280209.
    >> Share

  72. ZENIN V, Tsedilin A, Yurkova M, Siniavin A, et al
    Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities.
    PLoS One. 2023;18:e0286752.
    >> Share

  73. SMITH C, Fought AJ, Sung JF, McKinney JR, et al
    Congenital malformations and preeclampsia associated with integrase inhibitor use in pregnancy: A single-center analysis.
    PLoS One. 2023;18:e0276473.
    >> Share

  74. ROSEN EP, White N, Gilliland WM Jr, Gerona RR, et al
    Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305.
    PLoS One. 2023;18:e0287449.
    >> Share

  75. PENNER J, Ombajo LA, Otieno D, Nkuranga J, et al
    High rates of kidney impairment among older people (>/= 60 years) living with HIV on first-line antiretroviral therapy at screening for a clinical trial in Kenya.
    PLoS One. 2023;18:e0285787.
    >> Share

  76. SAHAY S, Bangar S, Chandhiok N
    Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men (MSM) and transgender women (TGW) in India: Study protocol.
    PLoS One. 2023;18:e0287454.
    >> Share

  77. PINKOH R, Rodsiri R, Wainipitapong S
    Retrospective cohort observation on psychotropic drug-drug interaction and identification utility from 3 databases: Drugs.com(R), Lexicomp(R), and Epocrates(R).
    PLoS One. 2023;18:e0287575.
    >> Share

  78. NATUKUNDA E, Szubert A, Otike C, Namyalo I, et al
    Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.
    PLoS One. 2023;18:e0288877.
    >> Share

  79. TUKEI VJ, Herrera N, Masitha M, Masenyetse L, et al
    Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
    PLoS One. 2023;18:e0288619.
    >> Share

  80. BRADSHAW D, Abramowicz I, Bremner S, Verma S, et al
    Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease.
    PLoS One. 2023;18:e0288598.
    >> Share

  81. SQUILLACE N, Ricci E, Maggi P, Taramasso L, et al
    Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
    PLoS One. 2023;18:e0289132.
    >> Share

  82. SHOAIB TH, Ibraheem W, Abdelrahman M, Osman W, et al
    Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies.
    PLoS One. 2023;18:e0289887.
    >> Share

  83. MBEBI ENONE PJ, Penda CI, Ngondi G, Fokam J, et al
    High risk of virologic failure among HIV-infected children and adolescents routinely followed-up in Littoral region of Cameroon.
    PLoS One. 2023;18:e0289426.
    >> Share

  84. KIM J, Newcomb CW, Carbonari DM, Torgersen J, et al
    Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012-2016.
    PLoS One. 2023;18:e0290889.
    >> Share

  85. MENDOZA I, Lazaro A, Espinosa A, Sanchez L, et al
    Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
    PLoS One. 2023;18:e0291480.
    >> Share

  86. SOUZA KM, Carrasco G, Rojas-Cortes R, Michel Barbosa M, et al
    Effectiveness of nirmatrelvir-ritonavir for the treatment of patients with mild to moderate COVID-19 and at high risk of hospitalization: Systematic review and meta-analyses of observational studies.
    PLoS One. 2023;18:e0284006.
    >> Share

  87. MOUSAVI MOVAHED SM, Akhavizadegan H, Dolatkhani F, Akbarpour S, et al
    Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study.
    PLoS One. 2023;18:e0292746.
    >> Share

  88. LEUNG V, Gill S, Llanes A, Khawaja A, et al
    A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.
    PLoS One. 2023;18:e0293302.
    >> Share

  89. AKISO M, Ameka M, Naidoo K, Langat R, et al
    Metabolic and mitochondrial dysregulation in CD4+ T cells from HIV-positive women on combination anti-retroviral therapy.
    PLoS One. 2023;18:e0286436.
    >> Share

  90. NIGHTINGALE S, Ssemmanda S, Tucker LM, Eastman RW, et al
    Electroencephalography as a diagnostic tool for late-onset efavirenz neurotoxicity syndrome.
    PLoS One. 2023;18:e0288055.
    >> Share

  91. BLAYLOCK JM, Ewers EC, Bianchi EJ, King DB, et al
    Risk of sexually transmitted infections among U.S. military service members in the setting of HIV pre-exposure prophylaxis use.
    PLoS One. 2023;18:e0296054.
    >> Share

    January 2022
  92. NGAYO MO, Oluka M, Kwena ZA, Bulimo WD, et al
    Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    PLoS One. 2022;17:e0260872.
    >> Share

  93. T TCHAKOUTE C, Rhee SY, Hare CB, Shafer RW, et al
    Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system.
    PLoS One. 2022;17:e0263742.
    >> Share

  94. MARTINEZ CA, Rikhi R, Pester MS, Parker M, et al
    Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV.
    PLoS One. 2022;17:e0264445.
    >> Share

  95. FENTIE WENDIE T, Mengistu G
    Prevalence and predictors of anemia among adults on highly active antiretroviral therapy in Northeast Ethiopia: A retrospective cohort study.
    PLoS One. 2022;17:e0265337.
    >> Share

  96. FISEHA T, Ebrahim H, Ebrahim E, Gebreweld A, et al
    CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
    PLoS One. 2022;17:e0265740.
    >> Share

  97. KIM JH, Jiamsakul A, Kiertiburanakul S, Huy BV, et al
    Patterns and prognosis of holding regimens for people living with HIV in Asian countries.
    PLoS One. 2022;17:e0264157.
    >> Share

  98. HONG SY, Winston A, Mutenda N, Hamunime N, et al
    Predictors of loss to follow-up from HIV antiretroviral therapy in Namibia.
    PLoS One. 2022;17:e0266438.
    >> Share

  99. VELLOZA J, Poovan N, Ndlovu N, Khoza N, et al
    Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial.
    PLoS One. 2022;17:e0266665.
    >> Share

  100. EJIGU S, Haile D, Solomon Y
    Effect of malaria and HIV/AIDS co-infection on red blood cell indices and its relation with the CD4 level of patients on HAART in Bench Sheko Zone, Southwest Ethiopia.
    PLoS One. 2022;17:e0263865.
    >> Share

  101. ELMEKATY EZI, Alibrahim R, Hassanin R, Eltaib S, et al
    Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
    PLoS One. 2022;17:e0267884.
    >> Share

  102. HONG W, Park YK, Kim BO, Park SK, et al
    Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.
    PLoS One. 2022;17:e0267645.
    >> Share

  103. ROSENTHAL EM, Rosenberg ES, Patterson W, Ferguson WP, et al
    Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State.
    PLoS One. 2022;17:e0268978.
    >> Share

  104. ACHILA OO, Abrhaley F, Kesete Y, Tesfaldet F, et al
    Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea.
    PLoS One. 2022;17:e0270838.
    >> Share

  105. SKRZAT-KLAPACZYNSKA A, Paciorek M, Horban A, Kowalska JD, et al
    Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients.
    PLoS One. 2022;17:e0270770.
    >> Share

  106. AKTER Y, Barua R, Nasir Uddin M, Muhammad Sanaullah AF, et al
    Bioactive potentiality of secondary metabolites from endophytic bacteria against SARS-COV-2: An in-silico approach.
    PLoS One. 2022;17:e0269962.
    >> Share

  107. MESIC A, Decroo T, Mar HT, Jacobs BKM, et al
    Viraemic-time predicts mortality among people living with HIV on second-line antiretroviral treatment in Myanmar: A retrospective cohort study.
    PLoS One. 2022;17:e0271910.
    >> Share

  108. BUSKIN SE, Lechtenberg RJ, Slaughter FA, Herbeck JT, et al
    A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis.
    PLoS One. 2022;17:e0272958.
    >> Share

  109. EBONWU J, Lassauniere R, Paximadis M, Strehlau R, et al
    FCGR3A gene duplication, FcgammaRIIb-232TT and FcgammaRIIIb-HNA1a associate with an increased risk of vertical acquisition of HIV-1.
    PLoS One. 2022;17:e0273933.
    >> Share

  110. MWAMUYE IC, Karanja S, Msanzu JB, Adem A, et al
    Factors associated with poor outcomes among people living with HIV started on anti-retroviral therapy before and after implementation of "test and treat" program in Coastal Kenya.
    PLoS One. 2022;17:e0270653.
    >> Share

  111. KARONEY MJ, Koech MK, Njiru EW, Owino Ong'or WD, et al
    Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya.
    PLoS One. 2022;17:e0273183.
    >> Share

  112. BOYCE CL, Beck IA, Styrchak SM, Hardy SR, et al
    Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    PLoS One. 2022;17:e0275254.
    >> Share

  113. THURMAN AR, Brache V, Cochon L, Ouattara LA, et al
    Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.
    PLoS One. 2022;17:e0275794.
    >> Share

  114. GOODE-ROMERO G, Dominguez L
    Computational study of the structural ensemble of CC chemokine receptor type 5 (CCR5) and its interactions with different ligands.
    PLoS One. 2022;17:e0275269.
    >> Share

  115. PENDA CI, Moukoko Mbonjo M, Fokam J, Djeuda ABD, et al
    Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
    PLoS One. 2022;17:e0276730.
    >> Share

  116. NAKIGANDA LJ, Grulich AE, Poynten IM, Serwadda D, et al
    Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda.
    PLoS One. 2022;17:e0277226.
    >> Share

  117. KIMANGA DO, Oramisi VA, Hassan AS, Mugambi MK, et al
    Uptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in Kenya.
    PLoS One. 2022;17:e0277675.
    >> Share

  118. WATTANACHANYA L, Sunthornyothin S, Apornpong T, Lwin HMS, et al
    Bone mineral density among virologically suppressed Asians older than 50 years old living with and without HIV: A cross-sectional study.
    PLoS One. 2022;17:e0277231.
    >> Share

  119. CABELLO-UBEDA A, de Quiros JCLB, Martin Carbonero L, Sanz J, et al
    48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naive adults living with HIV: A multicenter real-life cohort.
    PLoS One. 2022;17:e0277606.
    >> Share

  120. HSIAO K, Zegzouti H, Goueli S
    High throughput bioluminescent assay to characterize and monitor the activity of SARS-CoV-2 methyltransferases.
    PLoS One. 2022;17:e0274343.
    >> Share

  121. ZHU J, Huang H, Wang M, Zhang Y, et al
    High baseline body mass index predicts recovery of CD4+ T lymphocytes for HIV/AIDS patients receiving long-term antiviral therapy.
    PLoS One. 2022;17:e0279731.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016